Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 subcutaneous Bicillin L-A infusion for secondary prophylaxis in rheumatic fever/rheumatic heart disease
ACTRN12622000916741Phase 2Recruiting
- Sponsor
- University of Otago
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benzylpenicillin in rheumatic fever (RF) and rheumatic heart disease (RHD), sponsored by University of Otago. Primary endpoints: Time above minimum inhibitory concentration, Pain after subcutaneous infusion and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
benzylpenicillin
03
Conditions
rheumatic fever (RF)rheumatic heart disease (RHD)
Beyond the preview
Go deeper on ACTRN12622000916741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000916741.